vamtam-theme-circle-post Category Press Science is a Puzzle: Selux Diagnostics Director of Research and Development Kelly Flentie On Collaboration, Idea Diversity, and Solving One of the Biggest Medical Problems of Our Time April 26, 2022 Read More vamtam-theme-circle-post Category Press Selux Diagnostics pulls in $50m Series C March 3, 2022 Read More vamtam-theme-circle-post Category Press Selux secures $50M for commercialization of antimicrobial susceptibility testing platform March 3, 2022 Read More vamtam-theme-circle-post Category Press Selux Diagnostics Eyes First Half of 2022 for Next-Gen AST Platform Launch November 16, 2021 Read More vamtam-theme-circle-post Category Press Breakthrough device designation for AST platform October 4, 2021 Read More vamtam-theme-circle-post Category Press Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform September 28, 2021 Read More vamtam-theme-circle-post Category Press Selux wins FDA breakthrough device designation for phenotyping platform September 28, 2021 Read More vamtam-theme-circle-post Category Press Health Tech: Aleksandar Vacic On How Selux Diagnostics’s Technology Can Make An Important Impact In Our Overall Wellness August 19, 2021 Read More vamtam-theme-circle-post Category Press BARDA grants additional funding for rapid antibiotic susceptibility test June 14, 2021 Read More vamtam-theme-circle-post Category Press Selux Diagnostics receives additional $14.6M in BARDA funding after successfully completing first clinical trial June 14, 2021 Read More Page 1 of 41 2 3 4 Next
